Trial Profile
A Phase 2 Trial to Evaluate the Efficacy of PRM-151 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Zinpentraxin alfa (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Sponsors Promedior; Roche
- 05 Jun 2019 This trial has been completed in Czech Republic, according to European Clinical Trials Database.
- 20 May 2019 Results published in the Media Release
- 20 May 2019 According to a Promedior media release, results were simultaneously published in The Lancet Respiratory Medicine and presented at the American Thoracic Society 2019 International Conference.